MTOR and neoplasm: Along these lines, we showed that PRT1419 and PRT2527 combine with and enhance the anti-tumor effects of TKIs (Sunitinib, Pazopanib, Cabozantinib), mTOR inhibitors (Everolimus) and HIF2a inhibitors (Belzutifan).